Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Financial Results

Starling Oncology Revenue Grows to $169.77 Million in Q3 2026 on Specialty Pharmacy Gains

Starling Oncology reported a 24.3% increase in third-quarter revenue, reaching $169.77 million, primarily driven by strong performance in its Specialty Pharmacy segment. While the company narrowed its net loss to $15.75 million, it continues to manage a significant stockholders' deficit as it scales its value-based care model.

Herbal tea, teabags, beverage, camomile. Stock photo illustrating Starling Oncology's financial results story.
Starling Oncology, Inc. · Photo: stevepb / Pixabay
Results at a glance · $ Million
Metric Q3-26Q3-25
Revenue 169.77136.56
Pretax Income -15.75-16.50
Net Income -15.75-16.50
Diluted EPS -0.13-0.14
Net Income YoY
+4.6%

Key highlights

  • Consolidated revenue increased to $169.77 million from $136.56 million in Q3 2025
  • Net loss narrowed by 4.6% year-over-year to $15.75 million
  • Nine-month revenue reached $478.5 million, up from $403.7 million in the prior year
  • Full-year 2026 revenue guidance established at $650 million to $660 million
  • Specialty Pharmacy segment remains the primary driver of top-line expansion

How the Period Went

Starling Oncology achieved significant top-line growth in the third quarter of 2026, with revenue rising to $169.77 million from $136.56 million in the same period last year. This 24.3% increase follows a consistent upward trend throughout the fiscal year, with revenue climbing sequentially from $147.4 million in the first quarter and $161.3 million in the second. Profitability metrics also showed moderate improvement; the company reported a net loss of $15.75 million, or $0.13 per diluted share, representing a 4.6% narrowing from the $16.50 million loss recorded in Q3 2025. This performance aligns with a year-to-date revenue total of $478.5 million for the first nine months of 2026.

Margins and Profitability

Despite the robust revenue growth, Starling Oncology remains in a net loss position, reporting a cumulative loss of $28.0 million for the nine months ended September 30, 2026. This ongoing lack of GAAP profitability is reflected in a total stockholders' deficit of $37.4 million. However, the company is trending toward operational break-even on an adjusted basis, according to market data from MarketBeat, which notes a full-year Adjusted EBITDA guidance range of $4 million to $6 million. The Specialty Pharmacy segment has been instrumental in supporting these margins, balancing the higher costs associated with the company’s community clinic infrastructure and its value-based capitated care arrangements.

Business Overview

  • Operates a network of community oncology clinics and specialized dispensaries across multiple states
  • Utilizes a value-based care model, including capitated arrangements where providers receive fixed fees per patient
  • Primary revenue growth is currently driven by the Specialty Pharmacy segment and increased prescription capture rates
  • The company rebranded from The Oncology Institute in mid-2026 to reflect its coordinated-care evolution
  • Does not maintain an order backlog due to the nature of clinical oncology and pharmaceutical service delivery
  • Employs a proprietary technology platform, Starling Nexus, to manage prior authorizations and evidence-based pathways

Financial Context and Sector Trends

Starling Oncology's results come as the healthcare sector continues a shift toward value-based reimbursement models. The company’s increased revenue guidance, now set at $650 million to $660 million, suggests confidence in its ability to scale patient encounters and pharmaceutical volume. This growth is notable compared to the $142.0 million revenue baseline seen in Q4 2025. A significant upcoming liquidity event includes the expiration of public redeemable warrants on November 12, 2026. This capital structure transition occurs as the company faces a sector landscape defined by rising drug costs and the expansion of the CMS Enhancing Oncology Model, which incentivizes the type of cost-efficient community care Starling provides.

Recent quarters and guidance
DateAnnouncementAmount
05 Nov 2026Q3 2026 consolidated revenue and FY 2026 guidance updateSource: globenewswire.com$169.8 Million
06 Aug 2026Q2 2026 consolidated revenue and FY 2026 guidance updateSource: investors.starlingoncology.com$161.3 Million
07 May 2026Q1 2026 consolidated revenue and FY 2026 guidance reaffirmationSource: stocktitan.net$147.4 Million
12 Mar 2026Q4 2025 consolidated revenue and initial FY 2026 guidanceSource: investors.starlingoncology.com$142.0 Million
13 Nov 2025Q3 2025 consolidated revenue and FY 2025 guidance increaseSource: stocktitan.net$136.6 Million
13 Aug 2025Q2 2025 consolidated revenue and FY 2025 guidance reaffirmationSource: seekingalpha.com$119.8 Million
Source verified

SEC filing by Starling Oncology, Inc. announcing its third-quarter 2026 financial results.

Read the filing ↗

Track Starling Oncology, Inc. live

Get the next Starling Oncology, Inc. SEC filing seconds after it lands.

More in Results & Earnings

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.